Recently, his team has applied cryo-EM to elucidation of the structure and dynamics of GPCRs. Prof. Sexton has published over 335 peer reviewed journal articles and has been cited >29,000 times (Google Rand Medal (ASCEPT), Paxinos-Watson Award (Australian Neuroscience Society), Vane Medal (BPS), Gordon Hammes

He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular Arey’s laboratory discovered the first described synthetic agonists and antagonists of the FSHR and has

He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular Arey’s laboratory discovered the first described synthetic agonists and antagonists of the FSHR and has

Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the

Adriano’s research has contributed to our understanding of the role that ubiquitin plays in GPCR signaling His lab has shown a role for -arrestins and PTMs in GPCR trafficking and signaling and has leveraged

Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the

She has done extensive work on the molecular pharmacology of opioid receptors and is currently focusing We chatted about how the current pandemic has affected her personally and professionally. Dr.

., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced through Phase 2 clinical trials. Bruns has over 80 publications and 11,000 citations, with an h-index of 47. Dr. Robert F.

More recently, his team has been at the forefront of the application of cryo-EM to elucidate of the structure Sexton has published over 320 peer-reviewed journal articles and has been cited >26,000 times (Google Rand Medal (ASCEPT), Paxinos-Watson Award (Australian Neuroscience Society), Vane Medal (BPS), Gordon Hammes

He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological His research career has focused on the investigation of the regulation of G protein-coupled receptors

Trejo’s research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation She has made numerous important discoveries related to the mechanisms that control PAR1 signaling and is the recognized expert on protease-activated receptors, particularly PAR1, and over the years she has Trejo has presented her studies at 52 national/international meetings and 66 academic seminars across GPCR About Anne Marie Quinn "Anne Marie Quinn has a long and varied work experience in the biocomputing

He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological His research career has focused on the investigation of the regulation of G protein-coupled receptors

He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development, many of which have progressed into clinical He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London He has published over 70 research articles, reviews and book chapters on drug discovery, which have been

He has 20+ years of experience in in vitro and in vivo GPCR pharmacology and has published seminal papers

David has over 20+ years of experience working in a drug discovery environment mainly in a specialist During this period David has made a significant contribution to the understanding of agonist/ antagonist

From that point on, Paul was hooked and has since studied receptor function in human physiology, receptor molecular pharmacology in cells, and animal models, and as he puts it has now he’s "gone full circle

Habilitus, he was appointed at the University of Bonn as a Professor of Pharmaceutical Chemistry declining Peter has been chaired Full Professor of Pharmaceutical / Medicinal Chemistry at the Friedrich-Alexander Peter Gmeiner has been spokesman of the Research Training Group "Medicinal Chemistry of Selective GPCR

About Heidi Hamm "Heidi E. Hamm, Ph.D. is the Aileen M. The Department’s strengths lie in GPCR signal transduction and neuroscience, and she has expanded it Her laboratory has been involved in studying G protein coupled signal transduction for many years and has made key discoveries in G protein structure and mechanisms of activation by GPCRs and activation She has received numerous awards, including the Glaxo Cardiovascular Discovery Award, the Distinguished

modeling, pharmacology) to study G protein-coupled receptors (GPCRs) and purinergic signaling and now has He has published more than 800 scientific publications, with an H-index of 115. His numerous awards include: 2008 Sato Award; 2009 Medicinal Chemistry Hall of Fame (American Chemical

Milligan has published more than 550 peer-reviewed articles and his research has been cited more than

PARs have an N-terminal leader sequence that is clipped by exogenous proteases to reveal a new N-terminus Our current goals are to explore this mechanism in detail and to understand how it may happen for the Tall has been continuously funded by the NIH since receiving an early RO1 award at Rochester. He has continued funding at Michigan through the MIRA R35 program. Dr. Tall has presented his work at 59 invited seminars including national and international meetings and

Future Leader Fellow and runs a laboratory of 7 Ph.D. and Honours students at UNSW Sydney, where she has Smith’s team has made advances in the understanding of how an orphan GPCR exerts its effects both in

Sri Kosuri Sri is a biologist that has helped build technologies, labs, and companies in synthetic biology His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene

Professor Pfleger has developed extensive expertise in profiling receptor binding and function at the He also has globally-recognized expertise in bioluminescence resonance energy transfer (BRET) technology He is Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research and Harry Kevin Pfleger on the web LinkedIn ResearchGate Pubmed Google Scholar University of Western Australia Harry

His work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular He has received substantial, long-term support from international and national competitive, charitable Professor Christopoulos has over 360 publications, including in leading international journals such as Nature,Science and Cell, and has delivered over 180 invited presentations. He has also been the recipient of multiple awards, including the John J.

nanoparticles can precisely initiate sustained endosomal signal transduction, while nanotechnology has Therefore, emerging evidence has revealed the interplay between GPCRs and nanoparticles, although investigations into their relationship have been inadequate. Nanotechnology has also been applied to construct synthetic nano-GPCRs or detect GPCRs, while endosomal

Since 2013, he has been elected Chair of the subcommittee for the Dopamine receptors of the International As of August 2022, he has over 270 publications in scientific journals (including Science, Nature, Cell

Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for insufficient understanding regarding of the receptor's structure and antibody recognition mechanism has